Loading...

Illumina, Inc.

ILU.DEXETRA
HealthcareMedical - Diagnostics & Research
72.92
-1.59(-2.13%)

Illumina, Inc. (ILU.DE) Stock Overview

Explore Illumina, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-2.93%
2.93%
Profit Growth
-6.07
5.34%
EPS Growth
-6.07
4.63%
Operating Margin
-12.84%
22.08%
ROE
-46.49%
5.34%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ILU.DEAnalyst Recommendations details for ILU.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

CEO

Mr. Jacob Thaysen Ph.D.

Employees

8,970

Headquarters

5200 Illumina Way, San Diego, CA

Founded

2007

Frequently Asked Questions